Best Therapy for Treatment-Resistant Depression: 2026 Ranked
Treatment-resistant depression (TRD) means depression that hasn't responded to at least two adequate trials of antidepressant medication — and it changes what "best therapy" even means. The right next step depends on how fast you need relief, whether trauma is driving the depression, and how much invasiveness you're willing to accept.
TL;DR
Ketamine-assisted therapy paired with psychotherapy is the strongest overall option for best therapy for treatment-resistant depression in 2026 when standard antidepressants have failed.
Esketamine (Spravato) is the only FDA-approved ketamine-based option, cleared in 2019 specifically for treatment-resistant depression.
ECT still produces the highest published response rates — around 60-70% — for severe or acute cases.
EMDR and trauma-focused therapy matter when depression is rooted in unresolved trauma, not just brain chemistry.
TMS gives a non-drug route with minimal systemic side effects for people who can't tolerate medication.
Best overall: ketamine-assisted therapy combined with psychotherapy integration. Best for an FDA-approved pharmacological route: esketamine (Spravato). Best budget or accessible option: augmented psychotherapy — CBT or psychodynamic therapy paired with medication management. Each fits a different situation, not a single leaderboard.
Why this matters
About a third of people treated for major depression don't get adequate relief from standard antidepressants, and every additional failed medication trial lowers the odds the next one works. That's the clinical definition of treatment-resistant depression, and it's why the conversation shifts from "which pill" to "which modality."
Higher Ground works with clients in Westport and Woodbury, Connecticut who've already tried medication and standard talk therapy without full relief. The options below aren't ranked by hype — they're ranked by evidence status, speed of relief, and who each one actually fits, in 2026.
What makes the best therapy for treatment-resistant depression
Evidence base — FDA approval status or peer-reviewed response-rate data, not anecdote
Speed of relief — hours to days versus the standard four-to-six-week antidepressant lag
Invasiveness and side-effect profile — outpatient talk therapy versus anesthesia-based procedures
Ability to pair with psychotherapy — does the modality create lasting change or just symptom suppression
Fit for trauma history — some depression is trauma-driven and needs a trauma-specific approach, not just biology-first treatment
Accessibility in 2026 — provider availability and insurance pathways in your state
Treatment options at a glance
Option | Best For | Standout Feature | Key Limitation |
Ketamine-assisted therapy | Rapid relief with psychotherapy integration | Effects can appear within hours to days | Requires in-office administration and monitoring |
Esketamine (Spravato) | FDA-approved, insurance-billable route | Only ketamine-based drug with full FDA approval for TRD | REMS-monitored administration, not take-home |
TMS | Non-drug option, minimal systemic side effects | No anesthesia, no cognitive side effects | Course runs over several weeks before full effect |
ECT | Severe or acute suicidal-risk cases | Highest published response rate of any option | Requires anesthesia; short-term memory effects possible |
EMDR / trauma-focused therapy | Depression rooted in trauma or PTSD overlap | Targets the trauma driving the depression, not just symptoms | Not a fit when trauma isn't the underlying driver |
Augmented psychotherapy (CBT/psychodynamic + meds) | Early-stage resistance, most accessible first step | Lowest barrier to entry, widest provider availability | Slower onset; less effective once resistance is severe |
Faster relief generally means a more clinical, monitored setting.
1. Ketamine-assisted therapy: best for rapid relief with psychotherapy integration
Ketamine-assisted therapy pairs low-dose ketamine administration with structured psychotherapy sessions, using the drug's rapid neuroplastic window to accelerate the work usually done in talk therapy alone. Higher Ground runs this as an integrated model in Westport and Woodbury rather than a standalone infusion, which is where most of the reported symptom improvement in published literature comes from — the therapy component, not the drug in isolation. Full cost detail is covered separately in how much ketamine therapy costs in Connecticut.
Ketamine-assisted therapy pros:
Symptom change can show up within hours to days rather than weeks
Pairing with psychotherapy addresses underlying patterns, not just chemistry
Works for patients who've already failed multiple antidepressant trials
Ketamine-assisted therapy cons:
Ketamine itself is used off-label for depression outside the esketamine formulation
Requires in-office sessions with monitoring, not a take-home prescription
Not yet as broadly insurance-covered as standard medication management
Verdict: the strongest overall pick for treatment-resistant depression when standard antidepressants have already failed and rapid relief matters.
2. Esketamine (Spravato): best for an FDA-approved pharmacological route
Esketamine is the nasal-spray formulation of ketamine that the FDA approved in 2019 specifically for treatment-resistant depression in adults, administered under REMS monitoring at a certified site. It's the only ketamine-derived option with full FDA approval for this indication, which matters for insurance conversations and for patients who want an evidence pathway with a formal regulatory stamp.
Esketamine pros:
Only ketamine-based drug carrying full FDA approval for TRD
Clinical trials behind the 2019 approval showed meaningful response in patients who'd failed multiple prior treatments
More consistent insurance pathways than off-label ketamine
Esketamine cons:
Must be administered at a certified clinic with two hours of post-dose monitoring
Doesn't include integrated psychotherapy by default
Not appropriate for patients with certain cardiovascular or psychotic-spectrum conditions
Verdict: the right pick when an FDA-approved, insurance-friendly pharmacological option is the priority.
3. TMS: best for a non-drug option with minimal systemic side effects
Transcranial magnetic stimulation uses magnetic pulses to stimulate the prefrontal cortex, and the FDA cleared it for treatment-resistant depression back in 2008. It's outpatient, doesn't require anesthesia, and avoids the systemic side effects that come with any medication or infusion-based approach.
TMS pros:
No systemic drug exposure, no anesthesia
No cognitive side effects reported at the population level in published trials
Well-established FDA clearance dating back to 2008
TMS cons:
Requires a course of daily sessions over several weeks before full benefit appears
Slower onset than ketamine-based approaches
Not typically paired with structured psychotherapy in the same visit
Verdict: consider this when medication side effects or drug interactions rule out other routes and you can commit to a multi-week course.
4. ECT: best for severe or acute suicidal-risk cases
Electroconvulsive therapy remains the treatment with the highest published response rates for severe treatment-resistant depression — commonly cited around 60-70% in psychiatric literature — and it's still the standard of care when a patient is at acute suicide risk or hasn't responded to anything else. It requires brief general anesthesia and is delivered in a hospital or specialized clinical setting.
ECT pros:
Highest response rate of any option on this list for severe cases
Effect can appear faster than most medication trials
Decades of clinical use and outcome data behind it
ECT cons:
Requires anesthesia and a hospital or specialized setting
Short-term memory effects are a documented possibility
Not the first step for mild-to-moderate resistance — reserved for severe or acute presentations
Verdict: appropriate for severe, acute, or safety-critical cases, not a first-line choice for moderate resistance.
5. EMDR and trauma-focused therapy: best when depression is trauma-driven
Eye Movement Desensitization and Reprocessing (EMDR) targets the traumatic memories that sometimes sit underneath depression that hasn't responded to standard treatment. Higher Ground offers EMDR alongside individual and family therapy for clients where trauma, not just neurochemistry, looks like the driver. Treating the trauma directly can move depression that's stalled on medication alone.
EMDR pros:
Directly addresses trauma that medication and general talk therapy often miss
No medication, no procedural risk
Can be combined with other approaches on this list, including ketamine-assisted therapy
EMDR cons:
Only effective when trauma is genuinely part of the clinical picture
Progress can take multiple sessions to build momentum
Not a substitute for pharmacological intervention in severe biological depression
Verdict: the right fit specifically when a trauma history is tangled up with the depression — not a general-purpose TRD treatment.
6. Augmented psychotherapy (CBT or psychodynamic + medication management): best budget and accessible option
Before escalating to procedural interventions, many patients haven't fully exhausted combining talk therapy with careful medication management — switching classes, adding an augmenting agent, and pairing it with structured CBT or psychodynamic work. It's the most widely available option and the one most insurance plans cover without prior authorization hurdles.
Augmented psychotherapy pros:
Widest provider availability and most straightforward insurance coverage
No procedural risk, no anesthesia, no monitored administration
Builds coping skills that carry forward regardless of what treatment comes next
Augmented psychotherapy cons:
Slower onset — typically weeks, not days
Less effective once resistance is more severe or long-standing
Requires consistent weekly commitment to show results
Verdict: the sensible starting point for earlier-stage resistance, before moving to ketamine-assisted therapy, esketamine, TMS, or ECT.
How this ranking was built
Each option was weighed against the same six criteria: FDA or published evidence status, speed of relief, invasiveness, ability to pair with psychotherapy, fit for trauma-driven depression, and accessibility in 2026. Ketamine-assisted therapy ranks first overall because it combines rapid relief with the lasting-change mechanism of psychotherapy — the two things that matter most once medication alone has failed.
Which therapy should you choose?
If you've failed multiple antidepressant trials and want the fastest realistic path to relief with lasting change, ketamine-assisted therapy paired with psychotherapy is the default recommendation for 2026. If an FDA-approved, insurance-pathway drug matters more than integrated therapy, esketamine is the better fit. If trauma sits underneath the depression, start with EMDR before or alongside any pharmacological route. Reserve ECT for severe or acute safety situations, and start with augmented psychotherapy if you haven't yet exhausted medication and talk-therapy combinations.
Talk through your options in Connecticut
Higher Ground offers ketamine-assisted therapy and EMDR in Westport and Woodbury, CT.
FAQ
What is the best therapy for treatment-resistant depression in 2026?
Ketamine-assisted therapy combined with psychotherapy is the strongest overall option for treatment-resistant depression in 2026, based on speed of relief and the added benefit of integrated talk therapy. Esketamine, TMS, and ECT remain the FDA-recognized alternatives depending on severity and drug tolerance.
Is ketamine therapy better than ECT for treatment-resistant depression?
ECT has the highest published response rates (around 60-70%) for severe, acute cases, while ketamine-assisted therapy offers faster onset with lower invasiveness for moderate-to-severe resistance. The choice depends on severity and safety risk, not a single winner.
How is treatment-resistant depression defined?
Treatment-resistant depression means depression that hasn't adequately responded to at least two separate antidepressant trials at proper dose and duration. Each additional failed trial lowers the odds the next medication alone will work.
Is esketamine the same as ketamine therapy?
No. Esketamine (Spravato) is an FDA-approved nasal spray cleared in 2019 specifically for treatment-resistant depression, while ketamine-assisted therapy typically uses off-label ketamine paired with structured psychotherapy sessions.
How long does TMS take to work for depression?
TMS is delivered as a course of daily outpatient sessions over several weeks, with full benefit typically appearing near the end of the course rather than in the first days. It carries no systemic drug exposure or anesthesia risk.
Does EMDR help with depression that hasn't responded to medication?
EMDR helps specifically when unresolved trauma is driving the depression, not general biological depression. It's most effective paired with, not instead of, medication or other TRD-specific treatments when trauma is part of the clinical picture.
When is ECT recommended over other treatment-resistant depression options?
ECT is typically reserved for severe or acute cases, including active suicide risk, where its higher published response rate outweighs the anesthesia requirement and possible short-term memory effects.
One last thing
The detail most patients miss: ketamine-based approaches work on a fundamentally different biological timeline than SSRIs. Standard antidepressants need four to six weeks to show effect because they work through gradual receptor changes, while ketamine's effect on neuroplasticity can register within hours — which is exactly why it moved to the front of the treatment-resistant depression conversation once esketamine cleared FDA approval in 2019.
